US20170136147A1 - Skin graft product - Google Patents
Skin graft product Download PDFInfo
- Publication number
- US20170136147A1 US20170136147A1 US15/364,921 US201615364921A US2017136147A1 US 20170136147 A1 US20170136147 A1 US 20170136147A1 US 201615364921 A US201615364921 A US 201615364921A US 2017136147 A1 US2017136147 A1 US 2017136147A1
- Authority
- US
- United States
- Prior art keywords
- skin
- wound
- cells
- patient
- skin cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/362—Skin, e.g. dermal papillae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/10—Hair or skin implants
- A61F2/105—Skin implants, e.g. artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
- B29C64/10—Processes of additive manufacturing
- B29C64/106—Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
-
- B29C67/0055—
-
- B29C67/0085—
-
- B29C67/0088—
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y30/00—Apparatus for additive manufacturing; Details thereof or accessories therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y50/00—Data acquisition or data processing for additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y50/00—Data acquisition or data processing for additive manufacturing
- B33Y50/02—Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/08—Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/48—Automatic or computerized control
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
- C12N5/0698—Skin equivalents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0017—Angular shapes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
- A61F2240/002—Designing or making customized prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/64—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2089/00—Use of proteins, e.g. casein, gelatine or derivatives thereof, as moulding material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/753—Medical equipment; Accessories therefor
- B29L2031/7532—Artificial members, protheses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
- C12N2502/094—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Materials Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Sustainable Development (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
Abstract
An apparatus and method for the production of substitute skin that advantageously reduces the amount of donor dermal cells needed from non-wound areas of a patient having a wound to be auto-grafted is reduced by using all of the harvested skin cells. A 3D printer is used to construct a wound graft product from the harvested skin cells without wasting any of the harvested skin cells. In a case of an irregularly shaped wound, wastage of harvested skin associated with trimming is avoided.
Description
- The invention relates to the medical arts, more particularly, to tissue engineering especially tissue engineering in which three-dimensional printing technology is used.
- Healing wounds is a complex process of tissue repair and regeneration in response to injury. The healing response in skin wounds attempts to reconstitute a tissue similar to the original damaged one and this is accomplished via the concerted action of numerous skin cell types, collagens, cytokines, growth factors (GF s), chemokines, cell surface and adhesion molecules, as well as multiple extracellular matrix proteins. Autologous split-thickness skin grafting currently represents the most rapid, effective method of reconstructing large skin defects; however, in cases where a significant quantity of harvested graft is required, it represents yet another trauma to an already injured patient.
- Some patent literature and academic literature is mentioned as follows, generally in roughly chronological order:
- Wille, Jr., “Method for the formation of a histologically-complete skin substitute,” U.S. Pat. No. 5,292,655 issued Mar. 8, 1994;
- Bernard, et al., “Process for creating a skin substitute and the resulting skin substitute,” U.S. Pat. No. 5,639,654 issued Jun. 17, 1997;
- Bernard et al., “Skin substitute,” U.S. Pat. No. 5,667,961 issued Sep. 16, 1997;
- Wille, Jr., “Serum free medium for use in the formation of a histologically complete living human skin substitute,” U.S. Pat. No. 5,686,307 issued Nov. 11, 1997;
- Takai et al., “Wound healing composition using squid chitin and fish skin collagen,” U.S. Pat. No. 5,698,228 issued Dec. 16, 1997;
- Wille, Jr., “Cell competency solution for use in the formation of a histologically-complete, complete, living, human skin substitute,” U.S. Pat. No. 5,795,781 issued Aug. 18, 1998;
- S. Hybbinette et al., “Enzymatic dissociation of keratinocytes from human skin biopsies for in vitro cell propagation,” Exp Dermatol., 1999: Feb; 8(1):30-8;
- Mares-Guia, “Non-immunogenic, biocompatible macromolecular membrane compositions, and methods for making them,” U.S. Pat. No. 6,262,255 issued Jul. 17, 2001;
- D. W. Hutmacher, “Scaffold design and fabrication technologies for engineering tissues—state of the art and future perspectives,” J. Biomater. Sci. Polymer Edn, 12:1, 107-124 (2001);
- Conrad et al., “Skin substitutes and uses thereof,” US 20020164793 published Nov. 7, 2002;
- Ramos et al., “Method for the preparation of immunologically inert amniotic membranes,” US 20040126878 published Jul. 1, 2004;
- Conrad et al., “Skin substitutes and uses thereof,” U.S. Pat. No. 6,846,675 issued Jan. 25, 2005;
- Conrad et al., “Skin substitutes and uses thereof',” US 20050226853 published Oct. 13, 2005;
- S. G. Priya, et al., “Skin Tissue Engineering for Tissue Repair and Regeneration,” Tissue Engineering: Part B, 14:1, 2008, 105-118;
- G. S. Schultz, et al., “Interactions between extracellular matrix and growth factors in wound healing,” Wound
Rep Reg 17, 153-162 (2009); - Conrad et al., “Skin substitutes and uses thereof,” U.S. Pat. No. 7,541,188 issued Jun. 2, 2009;
- Woodroof, “Laser-Perforated Skin Substitute,” US 20090230592 published Sep. 17, 2009;
- Woodroof, et al., “Artificial Skin Substitute,” US 20090232878 published Sep. 17, 2009;
- Woodroof; “Temporary Skin Substitute comprised of biological compounds of plant and animal origins,” US 20090234305 published Sep. 17, 2009;
- Woodroof, et al., “Skin Substitute Manufacturing Method,” US 20100000676 published Jan. 7, 2010;
- Woodroof, et al., “Artificial skin substitute,” U.S. Pat. No. 7,815,931 issued Oct. 19, 2010;
- Mirua, et al., “Skin Substitute Membrane, Mold, and Method of Evaluating External Preparation for Skin,” US 2011009881 5 published Apr. 28, 2011;
- Israelowitz et al., “Apparatus for the growth of artificial organic items, especially human or animal skin,” US 20110159582 published Jun. 30, 2011;
- Guenou, “Methods for Preparing Human Skin Substitutes from Human Pluripotent Stem Cells,” US 20110165130 published Jul. 7, 2011;
- Bush et al., “Bioengineered Skin Substitutes,” US 20110171180 published Jul. 14, 2011;
- Yoo et al., “Delivery system,” US 20110172611 published Jul. 14, 2011;
- M. V. Karaaltin et al., “Adipose Derived Regenerative Cell Therapy for Treating a Diabetic Wound: A Case Report,” Oct. 6, 2011;
- Chernokalskaya, et al., “Polymeric Membranes with Human Skin-like Permeability Properties and uses thereof,” US 20110281771 published Nov. 17, 2011;
- Miura et al., “Application method of external dermatological medications, evaluating method of the same, application evaluating apparatus, and application evaluating program,” US 20120022472 published Jan. 26, 2012;
- D. Rosenblatt, “Researchers aim to ‘print’ human skin,” Feb. 15, 2011, www.cnn.com;
- Miura et al., “Skin substitute membrane, mold, and method of evaluating external preparation for skin,” US 20120109300 published May 3, 2012;
- R. Kirsner, et al., “Spray-applied cell therapy with human allogeneic fibroblasts and kertinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial,” www.thelancet.com, vol. 380, Sep. 15, 2012;
- B. Raelin, “Wake Forest 3D Prints Skin Cells Onto Burn Wounds,” Jul. 19, 2012, www.3dprinter-world. com;
- A. Lutz, “Printed Skin Cells Will Change How We Treat Burns Forever”, Aug. 03, 2012, www.businessinsider.com;
- Miura et al., “Skin substitute membrane, mold, and method of evaluating external preparation for skin,” U.S. Pat. No. 8,337,554 issued Dec. 25, 2012;
- “Printing Skin,” www.medicaldiscoverynews.com/shows/202 printSkin.html, undated;
- C. M. Zelen, et al., “A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers,” International Wound Journal, ISSN 1742-4801, 2013;
- H. Kim, et al., “Evaluation of an Amniotic Membrane-Collagen Dermal Substitute in the Management of Full-Thickness Skin Defects in a Pig,” Archives of Plastic Surgery, 2013, 40:1, 11-18;
- “SkinPrint: 3D Bio-printed human skin can help burn victims”, May 06, 2013, www.3ders.org;
- K. Maxey, “3D Printed, Transplantable Skin in 5 Years?”, May 17, 2013, www.engineering.com;
- H. Briggs, “Artificial human ear grown in lab,” Jul. 31, 2013, www.bbc.co.uk;
- S. Leckart, “How 3-D Printing Body Parts Will Revolutionize Medicine,”Aug. 06, 2013, www.popsci.com;
- Thangapazham et al., “Hair follicle neogenesis,” US 20130209427 published Aug. 15, 20131
- T. Lu et al., “Techniques for fabrication and construction of three-dimensional scaffolds for tissue engineering,” Internat'l Journal of Nanomedicine, 2013:8, 337-350.
- Although there are a number of reports of skin autografts produced in vitro, they take weeks to generate—which is too long a waiting period for a patient whose wound needs treatment. Quicker production of skin autografts is an unmet need and unsolved problem.
- In several studies conducted using amniotic membrane (AM) in both acute and chronic wounds, much of the first round placement is absorbed into the body. In some cases, it takes as many of 3-4 full grafts of AM in order to result in full closure of the wound. Less graft being absorbed into the body so that it is unable to contribute to closing the wound is an unsolved problem.
- Another difficult unsolved problem has been that when an undamaged donor area of skin of a patient is harvested and used as an autograft for treating the patient's own wound, the donor site often becomes a non-healing wound.
- There are complicated, unsolved problems and unmet needs for better technologies in wound grafting and wound healing.
- The invention addresses the above-described problems by processing ALL of the harvested skin cells taken from a healthy donor site on the patient with the wound to construct a customized skin graft product to be auto-grafted onto the wound. Production of a customized skin graft preferably is accomplished by operation of a three-dimensional (“3D”) printer, which is supplied with substrate material and autologous skin cells and “prints” the supplied skin cells onto an agar plate or other surface.
- Advantageously the amount of donor dermal cells needed from non-wound areas of a patient having a wound to be auto-grafted is reduced by using all of the harvested skin cells. A 3D printer is used to construct a wound graft product from the harvested skin cells without wasting any of the harvested skin cells. In a case of an irregularly shaped wound, wastage of harvested skin associated with trimming is avoided. The invention's provision of a skin grafting method that requires only the least amount of precious skin of the donor site to be damaged is highly important given major functions of skin: acting as a protective barrier from environmental insults including trauma, radiation, harsh environmental conditions and infection, providing thermoregulation (through sweating, vasoconstriction or vasodilation) and controlling fluid loss. This minimization of skin damage provided by the invention, in addition to the ability to continually regenerate the necessary skin until healing is complete, represent major advances in wound care.
- A major objective of the invention is to use the patient's own skill cells to re-create a strong, persistent organ replacement solution.
- The invention in a preferred embodiment provides a computerized skin printing system, comprising: a quantity of living donor skin cells harvested from a non-wound area of a patient having a to-be-treated wound or tissue defect; a three-dimensional printer that processes the quantity of living donor skin cells harvested from a non-wound area of a patient having the wound or tissue defect, wherein the three-dimensional printer is under control of a controller connected to the three-dimensional printer; an imaging device (such as, e.g., an imaging device that comprises a camera; an imaging device that comprises a video camera; an imaging device that comprises a hand-held device; an imaging device that is movable to be positioned relative to the wound being imaged; etc.); and a computer that performs steps of receiving a set of images (such as, e.g., a set of one wound image; a set of multiple images) taken by the imaging device of the wound or tissue defect and processing the imaged wound or tissue defect into a set of skin-printing instructions that are provided to the controller connected to the three-dimensional printer; such as, e.g., a skin printing system further comprising a sizing grid that is projected onto the wound or tissue defect while the imaging device is being operated; a skin printing system further comprising a monitor connected to the computer; a skin printing system further comprising a keyboard connected to the computer; a skin printing system further comprising at least one syringe pump (such as e.g., a syringe pump that contains the quantity of living donor skin cells harvested from the non-wound area) under control of the controller; a skin printing system further comprising a surface onto which the three-dimensional printer prints a skin product (such as, e.g., a skin printing system wherein the skin product printed onto the surface corresponds to a model generated by the computer from the set of wound images); a skin printing system further comprising a pump, and wherein skin cells in a syringe are pumped by the pump into the three-dimensional printer; a skin printing system wherein the computer digitizes a wound image and models the digitized image into a set of printing instructions; a skin printing system further comprising an agar plate comprising the surface onto which the three-dimensional printer prints the skin product; a skin printing system wherein the three-dimensional printer is supplied with both a quantity of living skin cells from the patient with the imaged wound and a quantity of material not from the patient with the imaged wound (such as, e.g., collagen or another scaffold-building material as the non-patient material); a skin printing system further comprising a digitizer; and other inventive skin printing systems.
- In another preferred embodiment, the invention provides an autograft treatment method of a wound of a patient, comprising: preparing the wound to be imaged; imaging the wound to obtain a set of images (such as, e.g., a wound imaging step that comprises photographing the wound); based on the set of images of the wound, modeling (such as, e.g., three-dimensional modeling) a skin graft product, wherein the modeling is performed by a computer, processor, or other machine; harvesting dermal cells from a donor site of the patient; from the harvested dermal cells, preparing a live cell suspension; loading a plate into a three-dimensional printer (such as, e.g., a printer-loading step that comprises loading an agar gel plate onto a platen of the printer); constructing a scaffold onto the plate (such as, e.g., a scaffold-constructing step in which the scaffold is constructed using little or none of the live cell suspension; a scaffold-constructing step that comprises constructing a scaffold of collagen (such as, e.g., bovine collagen (such as, e.g., Bovine Collagen Type 1)); etc.); seeding the scaffold with cells from the live cell suspension, until the modeled skin graft product has been constructed; when the skin graft product has been constructed, removing the skin graft product from the printer and from the plate; and after the removing step, placing the skin graft product in the wound; such as inventive methods wherein in the harvesting step, an amount of dermal cells harvested is in approximately a 1:5 ratio of skin harvested to skin estimated to be needed to treat the wound by conventional skin grafting; inventive methods wherein in the harvesting step, a maximum size is a 4 cm2 split-thickness graft using standard dermatome techniques; inventive methods wherein in the harvesting step, an amount of dermal cells harvested is does not exceed a 1:5 ratio of cells harvested to cells estimated to be needed to treat the wound by conventional skin grafting; inventive methods comprising dissociating and culturing the harvested cells in a culture medium (such as methods comprising adding allogeneic fibroblasts and keratinocytes to the culture medium); inventive methods further comprising securing the skin graft product with sutures and covering the skin graft product with a bandage; inventive methods comprising constructing multiple skin graft products for a same wound; inventive methods comprising constructing a first skin graft product and a second skin graft product for a same wound, on different days; a method further comprising printing insulin into the skin graft product being constructed; a method further comprising printing or spraying amniotic membrane into the skin graft product being constructed; and other inventive methods.
- In another preferred embodiment, the invention provides a skin graft product constructed from skin cells of a patient having a wound, wherein an amount of patient skin cells is less than the patient skin cells that would be estimated to be needed to treat the wound if only the patient skin cells were used, such as, e.g., an inventive skin graft product consisting of: an amount of patient skin cells which is less than the patient skill cells that would be estimated to be needed to treat the wound by conventional skin grafting if only the patient skin cells were used; and an amount of material other than patient skin cells; an inventive skin graft product wherein the amount of patient skin cells is selected from the group consisting of: about ⅔ what would be estimated to be needed to treat the wound if only the patient skin cells were used; less than ⅔ what would be estimated to be needed to treat the wound if only the patient skin cells were used; less than ½ what would be estimated to be needed to treat the wound if only the patient skin cells were used; less than ⅓ what would be estimated to be needed to treat the wound if only the patient skin cells were used; less than ¼ what would be estimated to be needed to treat the wound if only the patient skin cells were used; and less than ⅕ what would be estimated to be needed to treat the wound if only the patient skin cells were used; an inventive skin graft product wherein the amount of material other than patient skin cells comprises one or more of bovine collagen, growth factors, amniotic membrane and cytokines; and other inventive skin graft products.
- In another preferred embodiment, the invention provides a method of treating a patient wound, comprising: constructing a set of custom skin graft products G1 . . . Gn customized to the wound; placing the custom skin graft product G1 onto the wound; and placing the custom skin graft product Gn onto the custom skin graft product Gn−1 already placed on the wound, such as, e.g., an inventive method comprising layering custom skin graft products onto the wound over a period of days; and other inventive methods.
- The invention in another preferred embodiment provides a method of avoiding wastage of dermal cells harvested for autografting to treat a wound of a patient, comprising: harvesting a quantity of skin cells from a non-wound site of the patient having the wound; processing all of the harvested quantity of skin cells into an autograft skin product without wasting or discarding any of the harvested quantity of skin cells (such as, e.g., a processing step that comprises three-dimensional printing of an irregular three-dimensional shape); and applying the autograft skin product onto the wound; such as, e.g., inventive methods further comprising meshing the autograft; inventive methods wherein a ratio of surface area of the wound to surface area of a harvest site is about 5 square inches of wound to 1 square inch of harvest site, which is expressed as a Wound/Harvest Areas Ratio of 5:1; inventive methods wherein a Wound/Harvest Areas Ratio is in a range of from 2:1 to 7:1; inventive methods wherein the Wound/Harvest Areas Ratio is in a range of from 5:1 to 7:1; and other inventive methods.
- The invention in another preferred embodiment provides an auto-grafting method for treating a wound of a patient, comprising: harvesting a quantity of skin cells from a patient; and auto-grafting onto the wound of the patient the quantity of harvested skin cells, with the quantity of autografted harvested skin cells being substantially equal to the quantity of harvested skin cells (such as, e.g., an auto-grafting step that comprises auto-grafting a three-dimensional irregularly-shaped skin graft product); an auto-grafting method further comprising constructing, via operation of a three-dimensional printer, a skin graft product comprising the quantity of harvested skin cells; and other inventive auto-grafting methods.
-
FIG. 1 is a diagram of a computerized skin printing system in an embodiment of the invention. -
FIG. 2 is a diagram of an inventive method of producing an inventive autograft product, in an embodiment of the invention. -
FIG. 3 is a diagram of steps in an inventive autologous grafting method. - In a dermal autograft that comprises a quantity of harvested patient dermal cells, the invention advantagously minimizes the quantity of harvested patient dermal cells that are needed for an autograft to cover a particular wound. For such minimization, harvested patient dermal cells (preferably ALL of the harvested patient dermal cells) are used in combination with a quantity of material which is NOT harvested patient dermal cells, to construct a dermal autograft product to be applied to a wound. Preferred construction methods for use in the invention are, e.g., a layering method performed by a 3D printer (such as, e.g., 3D printer 1 in
FIG. 1 ); a method in which a computerized skin printing system is used (such as a computerized skin printing system ofFIG. 1 , see Example 1 herein); etc. - A preferred example of material which is NOT harvested patient dermal cells and which is useable in the invention is collagen, such as, e.g., Bovine Collagen Type I; Collagen IV; etc. As to Collagen IV, see, e.g., M. Paulsson, “Basement Membrane Proteins: Structure, Assembly, and Cellular Interactions,” Critical Reviews in Biochemistry and Molecular Biology, 27(½): 93-127 (1992).
- The inventive methodology preferably is used to fabricate then print skin tissue using much smaller areas of donor skin (such as, e.g., no larger than 4 cm2 split-thickness grafts harvested using standard dermatome techniques) compared to conventional methodology. The invention's provision of the ability to use such smaller areas of donor skin corresponds to a significant reduction in skin injury and subsequently less opportunity for transformation into a chronic wound or other sequelae common to donor sites. Advantageously, the invention provides an improved ratio of wound area to donor site (such as a 5:1 ratio of wound area to donor site; a 6:1 ratio of wound area to donor site; a 7:1 ratio of wound area to donor site; etc.) compared to a grafting methodology having a 1:1 up to 3:1 ratio of wound area to donor site for a mesh graft. Advantageously, the invention is useable for a relatively small area of donor site to cover relatively much wound site, such as, e.g., being able to cover 5-7 times, or more, of the donor site.
- A preferred methodology of combining harvested patient dermal cells and other material which is NOT harvested patient dermal cells is for cells from the respective donor site and non-donor sources to be processed until ready for loading into a set of dispensers in a 3D printer, and the 3D printer is used to perform a printing process by which the patient dermal cells and other materials are printed into a unitary graft product.
- To obtain the patient dermal cells, preferably small split thickness skin grafts are created and epidermal cells harvested, after which the heterogeneous mixture of cell types comprising mainly fibroblasts and keratinocytes is dissociated and cultured using standard cell culture techniques. Preferably, to stimulate rapid proliferation, allogeneic fibroblasts and keratinocytes are added to culture media along with a cocktail including appropriate growth factors.
- In a preferred example of a printing process, autologous cells which have been incubated with allogeneic fibroblasts and keratinocytes are printed onto a bovine collagen matrix in the size, shape, and depth of the patient's particular wound. In a most preferred example, collagen is printed first, then skin cells are layered onto the collagen. Preferably the collagen matrix is fortified with growth factors, amniotic membrane, and specific cytokines which serve as an active extracellular matrix (ECM) and basement membrane structure. Such procedures are preferred in order to set in motion a process by which the partially autologous skin graft will mimic the architecture of the patient's own tissue.
- Following preparation of the wound bed, a skin structure produced according to the invention is transplanted into the analogous structure of the wound.
- An advantage of the invention is to use the patient's own skill cells to re-create a strong, persistent organ replacement solution.
- Additionally, the time in which the replacement product is produced is much faster than the weeks needed to generate skin autografts produced in vitro using conventional methodology. The current state of the science has not reported manipulating cell proliferation at the rate needed for a 3-7 day growing phase. By contrast, advantageously, 3D cell printing according to the invention using an enhanced cell proliferation method with a mixture of cell types, ECM proteins, growth factors, and cytokines greatly reduces the time for regeneration of an adequate skin graft suitable for transplantation and healing.
- Unlike skin substitutes such as the dermal matrices Alloderm (human cadaveric), Strattice, or Integra (porcine sources) which are cost prohibitive and can be immunoreactive, the invention advantageously is used to recreate or regenerate a patient's own skin, in the shape and depth analogous to the injury. The resulting graft is less expensive compared to the mentioned products and has a better chance to “take”. Addition of allogeneic cells bolster and enhance proliferation of the patient's own fibroblasts and keratinocytes, and provide a source of constituents such as extracellular matrix and growth factors.
- As may be further appreciated with reference to
FIG. 3 , an example of an inventive skin printing process is step-wise as follows: - 1) Preparing 301 the wound 300 (e.g., NPWT—to manage exudate, reduce/eliminate infection, create vascularized granular bed of tissue).
- 2) Photographing 302 the
wound 300. - 3) Automatically modelling 303 the to-be-produced graft in 3D from the wound photo.
- 4) Obtaining 304 dermal cells from donor site (estimating a ratio, such as estimating a 1:5 ratio).
- 5) Preparing 305 a live cell suspension using the dermal cells from the donor site.
- 6) Loading 306 a plate (such as an agar plate) into a 3D printer (such as by loading an agar plate onto a platen of a 3D skin printer).
- 7) Physically rendering 307 an acellular dermal matrix (ADM) scaffold with collagen (such as pre-processed Bovin Collagen Type I).
- 8) Seeding 308 the ADM scaffold with live cells processed from the autologous graft obtained in
step 4 of this Example (step 304 inFIG. 3 ). Note, ADM may contain allogeneic fibroblasts. This step is also accomplished by “printing” the cells onto the ADM. - 9) Removing 309 printed skin from the 3D printer and agar gel plate.
- 10) Performing a
step 310 of placing the printed skin in thewound 300, securing with sutures and covering with a suitable bandage. - An inventive method of producing an inventive autograft product also can be appreciated with reference to
FIG. 2 .Surgical instrument 18 is used to separate epidermis 19 from skin at a donor site preferably of a same patient who has wound 17 (FIG. 1 ). - Separated
epidermis 19 is processed 200 by enzymatic cell separation to produce separateddermal cells 19A which are dissolved 201 to produce adermal cell solution 19B. -
Dermal cell solution 19B is cultured 202 onto plates to provide plateddermal cells 19C and/or is split 203 intodermal cell solutions 19D (such as 70% confluency). - Cultured
dermal cells 19C anddermal cell solutions 19D are harvested 204, 205 to be transferred to 3D printer cell dispensers such asdispenser 20. - Examples of contents of 3D
printer cell dispenser 20 are, e.g., autologous fibroblasts, keratinocytes, ECM proteins, growth factors (GF s), cytokines. Examples of contents of 3Dprinter cell dispenser 21 are, e.g., GF, insulin, PDGF, eNOS. Examples of contents of 3Dprinter cell dispenser 22 are lyophyllized amniotic membrane. - A 3D printer (such as 3D printer 1 of
FIG. 1 ) prints 206 the contents of thedispensers substrate 23 to produce a cultured graft preferably comprising bovine collagen, media, growth factors (GF s), etc. - Optionally an
electrical field 207 is applied in a region of thesubstrate 23 duringprinting 206. - It will be appreciated that printing 206 from
dispensers printing 206 may be performed in various sequences. - An example of harvesting grafts is to harvest a first graft at 7 days (from when the epidermis was removed from the donor site), and to maintain other grafts unharvested for a period of time until needed through final closure.
- The invention may be further appreciated with reference to the following examples, without the invention being limited thereto.
- In one inventive example, as may be appreciated with reference to
FIG. 1 , an inventive computerized skin printing system comprises a three-dimensional (3D) printer 1. Preferably the 3D printer 1 is cooled or temperature-controlled. An example of a 3D printer 1 is a 3D printer capable of printing living cells. The 3D printer 1 comprises at least one dispenser head 2 from which emerges cells that are being printed onto a surface 3 (such as, e.g., an agar plate) which is accommodated on aplaten 4 within the 3D printer. The dispenser head 2 is attached to printhead 5 which is positionable in (x, y, z) dimensions, which positioning is controlled by controller 6. Controller 6 also controls a syringe pumping system 7. - Syringe pumping system 7 comprises
syringe 8 in which is contained skin cells harvested from the patient for whom the auto-graft product is being made and syringe 9 in which is contained material which does NOT include the patient's skin cells, such as, e.g., bovine collagen; allogeneic skin cells; etc. System 7 optionally comprises static mixers.Syringes 8, 9 supply the 3D printer 1 viatubes syringes 8, 9 to the dispenser head 2. - Controller 6 is electrically connected by
electrical connection 10 to the 3D printer 1 and byelectrical connection 11 to the pumping system 7. - Controller 6 is electrically connected via
data line 12 to acomputer 13. As an example ofcomputer 13 is a computer comprising a digitizer, the computer having software loaded thereon such as, e.g., software that digitizes an image of a wound and models the defect for printing; software that digitizes an image of a wound and automatically detects wound boundaries and models the defect for printing; etc. In some embodiments, wound boundaries are manually detected.Computer 13 receives human operator input via aninput device 14 which inFIG. 1 is illustrated as a keyboard but is not necessarily limited to a keyboard. A human operator reviews output fromcomputer 13 on amonitor 15. - Components illustrated separately in
FIG. 1 , such as, e.g.,input device 14 and monitor 15, are not necessarily required to be separate physical structures and can be integral with each other. Also, inFIG. 1 , cables or connecting lines that are illustrated are not necessarily required in all embodiments to be physical structures and in some embodiments a wireless connection is provided. -
Computer 13 is connected to animaging device 16 such as, e.g., a camera. Preferably imagingdevice 16 delivers video images tocomputer 13.Imaging device 16 is positionable to image a wound on a living patient, such as, e.g., being positionable via a stable structure such as an articulated arm, tripod, cart or frame. Imaging device comprises acomponent 16A (such as, e.g., a lens) which in operation is positioned in a direction of a wound orother tissue defect 17. Preferably a sizing guide (such as, e.g., a sizing grid) is provided in a region of the wound 17 (such as, e.g., a laser grid for sizing) while theimaging device 16 is imaging thewound 17. Preferably a laser sizing grid is projected onto and/or near thewound 17 to provide data for sizing the wound. In another embodiment, graticulated markers are positioned proximate the wound to provide sizing information to theimaging device 16. - Preferably
computer 13 performs steps of receiving a set of images taken by theimaging device 16 of the wound ortissue defect 17 and processing the imaged wound or tissue defect into a set of skin-printing instructions that are provided to the controller 6 connected to the 3D printer 1. - The system of
FIG. 1 is useable to process a quantity of living donor skin cells harvested from a non-wound area of a patient having the wound ortissue defect 17. - Application of the dissociated cells and other agents by the 3D printer, specifically, the configuration of the cell dispenser/applicator/syringe/air-brush, is dependent upon the type and depth of the wound. The number of “layers” or “passes” the cell dispenser must take with each agent applied to the collagen matrix in this Example is at least one layer.
- This approach of layering the patient's own fibroblasts, keratinocytes, etc., with commercially available amniotic membrane, growth factors, etc., is used to manipulate the healing process through wound supplementation with agents that are natural contributors to the wound healing process and specifically crucial for each particular wound type.
- Examples of techniques are as follows.
- Following harvest of the donor site, individual cells of the epidermal layer are dissociated from the dermis. Dissociation of skin cells is accomplished by traditional trypsin: EDTA methods which is a preferable method for isolating keratinocytes from human skin. Human serum, bovine serum albumin, serum fibronectin, type IV collagen, and laminin added to traditional cell culture media provide support to the fibroblasts and keratinocytes. These basement membrane protein constituents form the layers of the extracellular matrix on which these epidermal and dermal cells grow. They are present in every tissue of the human body. They are always in close apposition to cells and it is well known that they not only provide structural support in the form of an organized scaffold, but they also provide functional input to influence cellular behavior such as adhesion, shape, migration, proliferation, and differentiation. Disassociated cells are incubated and continually shaken in cell culture flasks at 37° C. Cells are sub-cultured prior to confluency and allowed either to continue to proliferate in dissociated cell suspension flasks, plated on collagen plates to continue growth, or plated via the skin printer onto bovine collagen substrates.
- In this Example, a bovine collagen matrix is augmented with growth factors such as Platelet-Derived Growth Factor (PDGF), epidermal Nitric Oxide Synthase (eNOS), Vascular Endothelial Growth Factor (VEGF), and Tumor Necrosis Factor Beta (TNF-beta). Low-dose insulin is added to also promote cell growth and proliferation. Insulin is a powerful growth factor that has been used in animal and human clinical trials of wound healing. Insulin has been used as a topical agent to accelerate the rate of wound healing and the proportion of wounds that heal in diabetic animals and in humans. Treatment with insulin also increased expression of eNOS, VEGF, and SDF-lalpha in wounded skin. Rezvani conducted an RCT in diabetic foot wounds to evaluate topical insulin on healing in 45 patients. The mean rate of healing was 46.09 mm2/day in the treatment group, and 32.24 mm2/day in the control group (p=0.03). These data suggest that insulin can improve wound healing and may be beneficial when used in an in vitro model to increase cell proliferation and would enhance cell proliferation into the collagen matrix.
- 3-4 days following the first application of autologous cells, and as the allogeneic cells and matrix begin to form obvious healthy epithelial tissue, lyophilized amniotic membrane (AM) is sprayed (such as from a modified airbrush-like apparatus (preferably associated with the print head of the 3D printer) onto the cell-seeded bovine collagen. There is a notable body of evidence to suggest that freeze-dried, powdered amniotic membrane promotes rapid healing and enhances the “take” rate of grafts. AM also inhibits natural inflammatory reactions which contribute to healthy tissue adhesion and structural development. There is evidence to suggest that combined with an electrical field, the application of AM will enhance cell migration and angiogenesis to cells located in the center-most region of the graft bed.
- Continual layers of the cultured material are printed onto collagen plates until desired thickness is achieved. Amount of cells wanted in each layer, number of times the printer must create layers for the skin graft, intervals between applications, and types and amounts of growth factors and other ECM proteins to be added are factors.
- Multiple copies of the autograft are printed. (In this example, multiple copies are printed. It will be appreciated that in other cases due to limited donor site material there will only be enough to print one copy.) The first is transplanted to the primary wound within 5-7 days. During the 5-7 days preparation period, negative pressure wound therapy with or without simultaneous irrigation (e.g., saline) is applied to prepare the wound bed for graft acceptance as well as reduce bacterial load. Negative pressure therapy is known to induce angiogenesis and this increase in blood flow and the resultant delivery of nutrients not only to the wound bed but to the newly placed engineered craft is critical to its survival and success.
- As was described hereinabove in the Background with respect to several studies conducted using amniotic membrane (AM) in both acute and chronic wounds, much of the first round placement was absorbed into the body. In some cases, it took as many of 3-4 full grafts of AM in order to result in full closure of the wound when using that conventional technology. By contrast, with skin printing according to the invention, a much thicker and partially autologous engineered graft that more closely approximates natural human skin is provided. A thicker, partially autologous engineered graft has improved probability of survival and ability to make active contributions to recruiting the active mechanisms of healing. Meanwhile, in practicing the invention, the additional skin grafts continue to mature and if necessary, are useable as the final step to closure. In the alternative, the graft copies could be stored in a tissue bank for later use by the same patient if, for example, additional surgical revisions were anticipated.
- While the invention has been described in terms of a preferred embodiment, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims.
Claims (6)
1-36. (canceled)
37. A skin graft product constructed from skin cells of a patient having a wound, wherein an amount of patient skin cells is less than the patient skin cells that would be estimated to be needed to treat the wound if only the patient skin cells were used.
38. The skin graft product of claim 37 , consisting of:
an amount of patient skin cells which is less than the patient skin cells that would be estimated to be needed to treat the wound by conventional skin grafting if only the patient skin cells were used;
an amount of material other than patient skin cells.
39. The skin graft product of claim 37 , wherein the amount of patient skin cells is selected from the group consisting of:
about ⅔ what would be estimated to be needed to treat the wound if only the patient skin cells were used;
less than ⅔ what would be estimated to be needed to treat the wound if only the patient skin cells were used;
less than ½ what would be estimated to be needed to treat the wound if only the patient skin cells were used;
less than ⅓ what would be estimated to be needed to treat the wound if only the patient skin cells were used;
less than ¼ what would be estimated to be needed to treat the wound if only the patient skin cells were used; and
less than ⅕ what would be estimated to be needed to treat the wound if only the patient skin cells were used.
40. The skin graft product of claim 38 , wherein the amount of material other than patient skin cells comprises one or more of bovine collagen, growth factors, amniotic membrane and cytokines.
41-53. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/364,921 US20170136147A1 (en) | 2013-11-20 | 2016-11-30 | Skin graft product |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/084,896 US9545302B2 (en) | 2013-11-20 | 2013-11-20 | Skin printing and auto-grafting |
US14/801,893 US20150366655A1 (en) | 2013-11-20 | 2015-07-17 | Skin printing and auto-grafting |
US15/364,921 US20170136147A1 (en) | 2013-11-20 | 2016-11-30 | Skin graft product |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/801,893 Division US20150366655A1 (en) | 2013-11-20 | 2015-07-17 | Skin printing and auto-grafting |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170136147A1 true US20170136147A1 (en) | 2017-05-18 |
Family
ID=53173520
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/084,896 Active 2034-06-20 US9545302B2 (en) | 2013-11-20 | 2013-11-20 | Skin printing and auto-grafting |
US14/801,893 Abandoned US20150366655A1 (en) | 2013-11-20 | 2015-07-17 | Skin printing and auto-grafting |
US15/352,027 Abandoned US20170072111A1 (en) | 2013-11-20 | 2016-11-15 | Skin printing and auto-grafting |
US15/364,968 Abandoned US20170136148A1 (en) | 2013-11-20 | 2016-11-30 | Auto-grafting |
US15/364,921 Abandoned US20170136147A1 (en) | 2013-11-20 | 2016-11-30 | Skin graft product |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/084,896 Active 2034-06-20 US9545302B2 (en) | 2013-11-20 | 2013-11-20 | Skin printing and auto-grafting |
US14/801,893 Abandoned US20150366655A1 (en) | 2013-11-20 | 2015-07-17 | Skin printing and auto-grafting |
US15/352,027 Abandoned US20170072111A1 (en) | 2013-11-20 | 2016-11-15 | Skin printing and auto-grafting |
US15/364,968 Abandoned US20170136148A1 (en) | 2013-11-20 | 2016-11-30 | Auto-grafting |
Country Status (1)
Country | Link |
---|---|
US (5) | US9545302B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140012225A1 (en) * | 2011-03-07 | 2014-01-09 | Wake Forest University Health Sciences | Delivery system |
CN107886571A (en) * | 2017-11-03 | 2018-04-06 | 中原工学院 | A kind of Mathematical Modeling Methods using computer hyperspace |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11877921B2 (en) | 2010-05-05 | 2024-01-23 | Markman Biologics Corporation | Method and apparatus for creating a modified tissue graft |
US11701213B2 (en) | 2010-05-05 | 2023-07-18 | Markman Biologics Corporation | Method and apparatus for creating a modified tissue graft |
WO2015110409A1 (en) | 2014-01-21 | 2015-07-30 | Smith & Nephew Plc | Wound treatment apparatuses |
US10279081B2 (en) | 2014-10-24 | 2019-05-07 | Allosource | Composite grafts, systems, and methods |
US11529436B2 (en) | 2014-11-05 | 2022-12-20 | Organovo, Inc. | Engineered three-dimensional skin tissues, arrays thereof, and methods of making the same |
WO2016119884A1 (en) * | 2015-01-30 | 2016-08-04 | Hewlett-Packard Development Company, L.P. | Generating previews of 3d objects |
JP2018512959A (en) | 2015-04-23 | 2018-05-24 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイテッド | Bilayer device for improved healing |
US9968437B2 (en) * | 2015-06-22 | 2018-05-15 | Bao Tran | 3D printer |
WO2017027353A1 (en) * | 2015-08-07 | 2017-02-16 | The Johns Hopkins University | Compositions and methods for modulating wound healing and regeneration |
CN105031713A (en) * | 2015-08-27 | 2015-11-11 | 华南理工大学 | 3D bio-printing medical dressing and preparation method thereof |
US10357962B2 (en) | 2016-03-08 | 2019-07-23 | Nike, Inc. | Printing utilizing a virtual mask |
US20190076577A1 (en) * | 2016-03-18 | 2019-03-14 | Allosource | Composite medical grafts and methods of use and manufacture |
CA3018119A1 (en) * | 2016-03-18 | 2017-09-21 | Allosource | Composite medical grafts and methods of use and manufacture |
CN106350437B (en) * | 2016-06-13 | 2019-10-15 | 暨南大学 | A kind of cell ball positioning biometric print device and method |
CN106110401B (en) * | 2016-06-30 | 2019-06-25 | 上海大学 | Micro-nano composite double layer dermal scaffold and preparation method thereof |
CN106073788B (en) * | 2016-07-19 | 2023-03-17 | 杭州捷诺飞生物科技有限公司 | OCT-based in-situ three-dimensional printing skin repair equipment and implementation method thereof |
CN106108984B (en) * | 2016-09-09 | 2018-09-11 | 福州大学 | A kind of personalized negative pressure sucker preparation method of leucoderma skin-grafting |
TWI608928B (en) * | 2016-10-14 | 2017-12-21 | 三鼎生物科技股份有限公司 | A method for three dimensional printing artificial skin |
CN106421916B (en) * | 2016-10-24 | 2019-02-22 | 广州润虹医药科技股份有限公司 | Organization engineering skin and preparation method thereof |
KR20190077407A (en) | 2016-11-10 | 2019-07-03 | 오가노보, 인크. | Bio-printed hair follicles and uses thereof |
CN108853702B (en) * | 2018-05-15 | 2021-02-26 | 中国科学院苏州生物医学工程技术研究所 | Novel intelligent medicine sprinkling system |
CN108392676A (en) * | 2018-05-15 | 2018-08-14 | 太原理工大学 | A kind of biology 3D printing full custom skin and preparation method thereof |
US11420391B2 (en) * | 2018-05-17 | 2022-08-23 | Diabase Prototyping And Engineering Llc | Cleaning mechanism for 3D printer |
WO2019241288A1 (en) * | 2018-06-11 | 2019-12-19 | The General Hospital Corporation | Skin construct transfer system and method |
TWI674201B (en) | 2018-09-10 | 2019-10-11 | 財團法人工業技術研究院 | Biomaterial printing apparatus |
BR112022009902A2 (en) * | 2019-11-22 | 2022-08-09 | Cutiss Ag | METHODS AND SYSTEMS FOR PRODUCTION OF SKIN GRAFTS |
CN115916109A (en) * | 2020-03-26 | 2023-04-04 | 马克曼生物制品公司 | Modified tissue grafts and methods and apparatus for creating modified tissue grafts |
CN112206357B (en) * | 2020-09-25 | 2021-12-28 | 清华大学 | Tissue engineering skin regeneration system |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2612938B1 (en) | 1987-03-26 | 1989-06-23 | Cird | METHOD FOR OBTAINING A SKIN EQUIVALENT AND CORRESPONDING SKIN EQUIVALENT |
FR2612939B1 (en) | 1987-03-26 | 1989-06-23 | Cird | SKIN EQUIVALENT |
US5292655A (en) | 1990-01-29 | 1994-03-08 | Wille Jr John J | Method for the formation of a histologically-complete skin substitute |
US6262255B1 (en) | 1995-04-05 | 2001-07-17 | Biomm, Inc. | Non-immunogenic, biocompatible macromolecular membrane compositions, and methods for making them |
JP2731833B2 (en) | 1995-06-26 | 1998-03-25 | 大同ほくさん株式会社 | Substitute skin made from marine life |
JP4299374B2 (en) | 1996-10-08 | 2009-07-22 | 高砂香料工業株式会社 | Cell activator and its application |
US8556983B2 (en) | 2001-05-25 | 2013-10-15 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs and related tools |
CA2379909C (en) | 1999-08-06 | 2011-01-04 | Board Of Regents, The University Of Texas System | Drug releasing biodegradable fiber implant |
DE19954166A1 (en) | 1999-11-10 | 2001-05-17 | Inst Textil & Faserforschung | Flat implant, method for its production and use in surgery |
US6554613B1 (en) | 2000-04-19 | 2003-04-29 | Ora Metrix, Inc. | Method and apparatus for generating an orthodontic template that assists in placement of orthodontic apparatus |
US7160110B2 (en) | 1999-11-30 | 2007-01-09 | Orametrix, Inc. | Three-dimensional occlusal and interproximal contact detection and display using virtual tooth models |
EP1279136A4 (en) | 2000-04-06 | 2005-02-09 | Solid Terrain Modeling | Hi-resolution three-dimensional imaging apparatus for topographic and 3d models |
US20010050031A1 (en) | 2000-04-14 | 2001-12-13 | Z Corporation | Compositions for three-dimensional printing of solid objects |
CN1277585C (en) | 2000-08-08 | 2006-10-04 | 阿德兰斯研究院有限公司 | Scaffolds for tissue engineered hair |
US6730252B1 (en) | 2000-09-20 | 2004-05-04 | Swee Hin Teoh | Methods for fabricating a filament for use in tissue engineering |
US7651507B2 (en) | 2003-03-03 | 2010-01-26 | Kci Licensing, Inc. | Tissue processing system |
NZ549527A (en) | 2001-03-02 | 2008-04-30 | Stratatech Corp | Improved skin substitutes and uses thereof |
PT102589A (en) | 2001-03-30 | 2002-12-31 | Ramos Maria Teresa Furtado | METHOD FOR PREPARING IMMUNOLOGICALLY INHERENT AMNIOTIC MEMBRANES |
DE10117875C1 (en) | 2001-04-10 | 2003-01-30 | Generis Gmbh | Method, device for applying fluids and use of such a device |
NL1017907C2 (en) | 2001-04-23 | 2002-10-25 | Cicero Dental Systems B V | Method for the manufacture of a dental restoration. |
US7353153B2 (en) | 2001-10-17 | 2008-04-01 | Maria-Grazia Ascenzi | Method and system for modeling bone structure |
US20030151167A1 (en) | 2002-01-03 | 2003-08-14 | Kritchman Eliahu M. | Device, system and method for accurate printing of three dimensional objects |
US8394371B2 (en) | 2002-02-11 | 2013-03-12 | Neocutis Sa | Compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same |
US8086336B2 (en) | 2002-09-30 | 2011-12-27 | Medical Modeling Inc. | Method for design and production of a custom-fit prosthesis |
US7662404B2 (en) | 2002-10-31 | 2010-02-16 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides |
IL152574A (en) | 2002-10-31 | 2009-09-22 | Transpharma Medical Ltd | Transdermal delivery system for dried particulate or lyophilized medications |
US7383084B2 (en) | 2002-10-31 | 2008-06-03 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
US8133505B2 (en) | 2002-10-31 | 2012-03-13 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
EP2295227A3 (en) | 2002-12-03 | 2018-04-04 | Stratasys Ltd. | Apparatus and method for printing of three-dimensional objects |
US7589868B2 (en) | 2002-12-11 | 2009-09-15 | Agfa Graphics Nv | Method and apparatus for creating 3D-prints and a 3-D printing system |
WO2004057916A2 (en) | 2002-12-19 | 2004-07-08 | Siemens Corporate Research, Inc. | Automatic binaural shell modeling for hearing aids |
US7051654B2 (en) * | 2003-05-30 | 2006-05-30 | Clemson University | Ink-jet printing of viable cells |
US7807077B2 (en) | 2003-06-16 | 2010-10-05 | Voxeljet Technology Gmbh | Methods and systems for the manufacture of layered three-dimensional forms |
EP1649008A2 (en) | 2003-07-16 | 2006-04-26 | Boston Scientific Limited | Aligned scaffolds for improved myocardial regeneration |
EP1682161A4 (en) | 2003-10-29 | 2011-12-07 | Gentis Inc | Polymerizable emulsions for tissue engineering |
US8119053B1 (en) | 2004-03-18 | 2012-02-21 | 3D Systems, Inc. | Apparatus for three dimensional printing using imaged layers |
EP1576957A1 (en) | 2004-03-18 | 2005-09-21 | Universiteit Twente | Tissue repair using pluripotent cells |
US7261542B2 (en) | 2004-03-18 | 2007-08-28 | Desktop Factory, Inc. | Apparatus for three dimensional printing using image layers |
GB0414277D0 (en) | 2004-06-25 | 2004-07-28 | Leuven K U Res & Dev | Orthognatic surgery |
US8071083B2 (en) | 2004-12-13 | 2011-12-06 | Progentix Orthobiology B.V. | Tissue regeneration |
CA2533998A1 (en) | 2005-01-27 | 2006-07-27 | Inspeck Inc. | Apparatus and method for producing a personalized 3d object |
EP1851268A4 (en) | 2005-02-23 | 2011-02-16 | Univ California | Flexible hydrogel-based functional composite materials |
EP1937326B1 (en) | 2005-10-21 | 2018-09-12 | CellResearch Corporation Pte Ltd | Isolation and cultivation of stem/progenitor cells from the amniotic membrane of umbilical cord and uses of cells differentiated therefrom |
US8147537B2 (en) | 2006-06-16 | 2012-04-03 | The Invention Science Fund I, Llc | Rapid-prototyped custom-fitted blood vessel sleeve |
US8095382B2 (en) | 2006-06-16 | 2012-01-10 | The Invention Science Fund I, Llc | Methods and systems for specifying a blood vessel sleeve |
EP2069296B1 (en) | 2006-09-28 | 2012-04-04 | Wisconsin Alumni Research Foundation | 2-methylene-(20s,25s)-19,27-dinor-(22e)-vitamin d analogs |
US7708557B2 (en) | 2006-10-16 | 2010-05-04 | Natural Dental Implants Ag | Customized dental prosthesis for periodontal- or osseointegration, and related systems and methods |
DE102006055054A1 (en) | 2006-11-22 | 2008-05-29 | Eos Gmbh Electro Optical Systems | Apparatus for layering a three-dimensional object |
DE102006055055A1 (en) | 2006-11-22 | 2008-05-29 | Eos Gmbh Electro Optical Systems | Apparatus for layering a three-dimensional object |
DE102006055074A1 (en) | 2006-11-22 | 2008-06-19 | Eos Gmbh Electro Optical Systems | Apparatus for layering a three-dimensional object and method for supplying building material |
DE102007002178A1 (en) | 2007-01-03 | 2008-07-10 | Aepsilon Rechteverwaltungs Gmbh | Method of modeling and making an artificial denture |
US8095210B2 (en) | 2007-01-19 | 2012-01-10 | California Institute Of Technology | Prosthetic devices and methods and systems related thereto |
DE102007014985A1 (en) | 2007-03-28 | 2008-10-02 | Aepsilon Rechteverwaltungs Gmbh | Method of making dental prostheses, method of creating a dataset and computer readable medium |
JP2009056656A (en) | 2007-08-30 | 2009-03-19 | Mimaki Engineering Co Ltd | Printer |
US8100692B2 (en) | 2007-10-19 | 2012-01-24 | Cagenix Incorporated | Dental framework |
US20090230592A1 (en) | 2008-03-15 | 2009-09-17 | Aubrey Woodroof | Laser-Perforated Skin Substitute |
US20090234305A1 (en) | 2008-03-15 | 2009-09-17 | Ernest Aubrey Woodroof | Temporary skin substitute comprised of biological compounds of plant and animal origins |
US7815931B2 (en) | 2008-03-15 | 2010-10-19 | Ernest Aubrey Woodroof | Artificial skin substitute |
US9155820B2 (en) | 2008-03-15 | 2015-10-13 | Aubergine Medical, Llc | Skin substitute manufacturing method |
US8366789B2 (en) | 2008-05-28 | 2013-02-05 | 3D Systems, Inc. | Prosthetic limb |
US8243334B2 (en) | 2008-06-06 | 2012-08-14 | Virginia Venture Industries, Llc | Methods and apparatuses for printing three dimensional images |
KR101032189B1 (en) | 2008-06-13 | 2011-05-02 | 가부시키가이샤 시세이도 | Evaluation method of skin substitute membrane and external skin preparation |
US20110165130A1 (en) | 2008-06-25 | 2011-07-07 | Inserm | Methods for Preparing Human Skin Substitutes from Human Pluripotent Stem Cells |
WO2010088699A2 (en) | 2009-02-02 | 2010-08-05 | Biomerix Corporation | Composite mesh devices and methods for soft tissue repair |
US20110171180A1 (en) | 2009-03-19 | 2011-07-14 | Worcester Polytechnic Institute | Bioengineered skin substitutes |
EP2233449B1 (en) | 2009-03-27 | 2014-12-17 | Ivoclar Vivadent AG | Use of a slip for the production of dental ceramics with hot melt inkjet printing methods |
CN102369429A (en) | 2009-03-30 | 2012-03-07 | 株式会社资生堂 | Method for applying external skin preparation, method for evaluating application by the method, device for evaluating the application and program for evaluating the application |
US8224006B2 (en) | 2009-08-28 | 2012-07-17 | Siemens Medical Instruments Pte. Ltd. | Hearing aid device and a method of manufacturing a hearing aid device |
EP2301741A1 (en) | 2009-09-28 | 2011-03-30 | Siemens Medical Instruments Pte. Ltd. | In-ear housing muffler or otoplastic |
US8175734B2 (en) | 2009-10-08 | 2012-05-08 | 3D M. T. P. Ltd. | Methods and system for enabling printing three-dimensional object models |
US8260589B1 (en) | 2009-12-24 | 2012-09-04 | Indian Institute Of Technology Madras | Methods and systems for modeling a physical object |
US20110159582A1 (en) | 2009-12-28 | 2011-06-30 | Biomimetics Technologies Inc | Apparatus for the growth of artificial organic items, especially human or animal skin |
EP2521587B1 (en) | 2010-01-08 | 2020-04-08 | Wake Forest University Health Sciences | Delivery system |
US8565909B2 (en) | 2010-02-24 | 2013-10-22 | Disney Enterprises, Inc. | Fabrication of materials with desired characteristics from base materials having determined characteristics |
SG184385A1 (en) | 2010-04-05 | 2012-11-29 | Emd Millipore Corp | Polymeric membranes with human skin like permeability properties and uses thereof |
US8543234B2 (en) | 2010-06-07 | 2013-09-24 | Fei Gao | Method and software system for treatment planning and surgical guide CAD/CAM |
WO2011160055A2 (en) | 2010-06-18 | 2011-12-22 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Hair follicle neogenesis |
US8425218B2 (en) | 2010-08-18 | 2013-04-23 | Makerbot Industries, Llc | Networked three-dimensional printing |
US8524312B2 (en) | 2011-11-16 | 2013-09-03 | Csl Silicones Inc. | Applicator for spraying elastomeric materials |
US8485820B1 (en) | 2011-12-22 | 2013-07-16 | Mohamed Ikbal Ali | Devices and methods for enhancing bone growth |
US10195644B2 (en) * | 2012-02-14 | 2019-02-05 | Board Of Regents, The University Of Texas System | Tissue engineering device and construction of vascularized dermis |
-
2013
- 2013-11-20 US US14/084,896 patent/US9545302B2/en active Active
-
2015
- 2015-07-17 US US14/801,893 patent/US20150366655A1/en not_active Abandoned
-
2016
- 2016-11-15 US US15/352,027 patent/US20170072111A1/en not_active Abandoned
- 2016-11-30 US US15/364,968 patent/US20170136148A1/en not_active Abandoned
- 2016-11-30 US US15/364,921 patent/US20170136147A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140012225A1 (en) * | 2011-03-07 | 2014-01-09 | Wake Forest University Health Sciences | Delivery system |
US10118005B2 (en) * | 2011-03-07 | 2018-11-06 | Wake Forest University Health Sciences | Delivery system |
US10537689B2 (en) | 2011-03-07 | 2020-01-21 | Wake Forest University Health Sciences | Delivery system |
US11759579B2 (en) | 2011-03-07 | 2023-09-19 | Wake Forest University Health Sciences | Delivery system |
CN107886571A (en) * | 2017-11-03 | 2018-04-06 | 中原工学院 | A kind of Mathematical Modeling Methods using computer hyperspace |
Also Published As
Publication number | Publication date |
---|---|
US9545302B2 (en) | 2017-01-17 |
US20150139960A1 (en) | 2015-05-21 |
US20170072111A1 (en) | 2017-03-16 |
US20170136148A1 (en) | 2017-05-18 |
US20150366655A1 (en) | 2015-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9545302B2 (en) | Skin printing and auto-grafting | |
US20160137979A1 (en) | Skin printing and auto-grafting | |
Urciuolo et al. | Bioengineered skin substitutes: the role of extracellular matrix and vascularization in the healing of deep wounds | |
Philandrianos et al. | Comparison of five dermal substitutes in full-thickness skin wound healing in a porcine model | |
Wood et al. | The use of a non-cultured autologous cell suspension and Integra® dermal regeneration template to repair full-thickness skin wounds in a porcine model: a one-step process | |
Fang et al. | Clinical application of cultured epithelial autografts on acellular dermal matrices in the treatment of extended burn injuries | |
Leirós et al. | Dermal papilla cells improve the wound healing process and generate hair bud-like structures in grafted skin substitutes using hair follicle stem cells | |
Pirayesh et al. | Glyaderm® dermal substitute: clinical application and long-term results in 55 patients | |
Willard et al. | Plant-derived human collagen scaffolds for skin tissue engineering | |
Biedermann et al. | Tissue engineering of skin for wound coverage | |
Climov et al. | Bioengineered self-assembled skin as an alternative to skin grafts | |
Saba et al. | Engineering tissues without the use of a synthetic scaffold: a twenty-year history of the self-assembly method | |
US10098986B1 (en) | Ready to use biodegradable and biocompatible artificial skin substitute and a method of preparation thereof | |
Tenenhaus et al. | Current concepts in tissue engineering: skin and wound | |
Zhang et al. | Advances in 3D skin bioprinting for wound healing and disease modeling | |
Tan et al. | Recent advances in the design of three-dimensional and bioprinted scaffolds for full-thickness wound healing | |
Nilforoushzadeh et al. | Tissue engineering in dermatology-from lab to market | |
Hartwell et al. | An in-situ forming skin substitute improves healing outcome in a hypertrophic scar model | |
Kang et al. | Advances and innovations of 3D bioprinting skin | |
Wallace et al. | Point of care approaches to 3D bioprinting for wound healing applications | |
Yildirimer et al. | Tissue‐Engineered Human Skin Equivalents and Their Applications in Wound Healing | |
Downer et al. | Current Biomaterials for Wound Healing | |
Somuncu et al. | Tissue engineering for skin replacement methods | |
Damaraju et al. | Skin substitutes with noncultured autologous skin cell suspension heal porcine full‐thickness wounds in a one‐stage procedure | |
Kumar et al. | Scaffolds for epidermal tissue engineering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INNOVATIVE THERAPIES, INC., FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TUMEY, DAVID;BERRIMAN, SANDRA;REEL/FRAME:040468/0020 Effective date: 20140102 |
|
AS | Assignment |
Owner name: DERMAGENESIS LLC, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INNOVATIVE THERAPIES, INC.;REEL/FRAME:040492/0328 Effective date: 20140304 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |